Regular paper
Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice

https://doi.org/10.1016/0014-2999(95)00026-HGet rights and content

Abstract

The antinociceptive potencies of 2-methyl-4aα-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aα-octahydro-quinolino[2,3,3-g]isoquinoline (TAN-67), a non-peptidic δ-opioid receptor agonist, were examined using the acetic acid abdominal constriction test and the tail-flick test in diabetic mice. TAN-67, at doses of 3–100 mg/kg, i.p., produced a marked and dose-dependent inhibition of the number of acetic acid-induced abdominal constrictions in both non-diabetic and diabetic mice. The antinociceptive effect of TAN-67 in the acetic acid abdominal constriction test in diabetic mice was greater than that in non-diabetic mice. Indeed, the ED50 (95% confidence limits) value of TAN-67 for the inhibition of acetic acid-induced abdominal constrictions in diabetic mice (6.0 (3.5–10.5) mg/kg) was significantly lower than that in non-diabetic mice (31.4 (14.2–69.4) mg/kg). The antinociceptive effect of TAN-67 was not antagonized by pretreatment with either β-funaltrexamine, a selective μ-opioid receptor antagonist, or nor-binaltorphimine, a selective κ-opioid receptor antagonist. When 7-benzylidenenaltrexone (0.3 mg/kg, s.c.), a selective δ1-opioid receptor antagonist, was administered 10 min before treatment with TAN-67, the antinociceptive effect of TAN-67 was significantly antagonized. However, naltriben, a selective δ2-opioid receptor antagonist, had no significant effect on the antinociceptive effect of TAN-67. Furthermore, in the tail-flick test, TAN-67 at doses of 3–30 mg/kg, i.p., also produced a marked and dose-dependent antinociceptive effect in diabetic mice, but not in non-diabetic mice. In conclusion, TAN-67 produced an antinociceptive effect through the activation of δ1-opioid receptors. Furthermore, the results of this study support our hypothesis that mice with diabetes are selectively hyperresponsive to δ1-opioid receptor-mediated antinociception.

Cited by (65)

  • Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands

    2022, Bioorganic and Medicinal Chemistry Letters
    Citation Excerpt :

    Meanwhile, ligands with selective agonistic activity on DOR or KOR are expected to be used as analgesics without addiction. We previously designed and synthesized the DOR selective agonist, (±)-TAN-67 (1), in the course of the development of addiction-free opioid analgesics.2,3 Unexpectedly, this compound did not show potent analgesic effect in vivo in spite of the potent DOR agonist activity in vitro.4

  • Zebrafish models relevant to studying central opioid and endocannabinoid systems

    2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • DOR<inf>2</inf>-selective but not DOR<inf>1</inf>-selective antagonist abolishes anxiolytic-like effects of the δ opioid receptor agonist KNT-127

    2014, Neuropharmacology
    Citation Excerpt :

    These results were consistent with our previous report with mice acetic acid test (Saitoh et al., 2011). In addition, another study also showed that the antinociceptive effects of a selective DOR agonist TAN-67 were abolished by pretreatment with BNTX, but not with NTB in the mice acetic acid writhing test and tail flick test (Kamei et al., 1995). Taken together, these results suggest that BNTX sensitive DOR1 subtype play important roles in the antinociceptive effects of DOR agonists in the inflammatory pain responses.

  • Novel δ1-receptor agonist KNT-127 increases the release of dopamine and l-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex

    2012, Neuropharmacology
    Citation Excerpt :

    Furthermore, no ESR signal was generated from dialysate, even at high KNT-127 concentration (1–100 nM) (data not shown). The δ-receptor is recognized as a novel neurotransmitter system that may be directly involved in neuropsychiatric disorders, i.e., chronic pain, schizophrenia, Parkinson’s disease, anxiety and mood disorders (Broom et al., 2002; Chang et al., 1993; Cryan et al., 2002; Kamei et al., 1995; Saitoh et al., 2011); however, peptide δ-receptor agonists cannot fully penetrate the blood–brain barrier (Nagase et al., 2010). Therefore, a number of small-molecular non-peptide δ-receptor agonists have become available for experimental use; they comprise compounds of different structures, such as the isoquinoline derivatives (TAN-67 and KNT-127) (Nagase et al., 2010, 2001) and the benzhydryl piperazine derivatives (SNC80 and BW373U86) (Bilsky et al., 1995; Chang et al., 1993).

View all citing articles on Scopus
View full text